Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Steve Gardner

CEO and co-founder, PrecisionLife

Photo of Dr Steve Gardner

Steve is a serial technology entrepreneur with over 25 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors. Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies. He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies. Steve has held CxO positions and led teams in several international businesses, supplying innovative computational biology, chemistry and semantic data integration tools. He was involved in Oxford Molecular’s IPO and the acquisition and integration of 11 companies. He is an Advisory Council member for Breast Cancer Now and UKCRC.        

Dr Veronique Bouchet

Chief Mecical Officer, PrecsionLife 

Photo of Dr Veronique Bouchet

Véronique is a medical expert and strategic thinker with over 30 years’ experience in the pharmaceutical, biotech anddigital health sectors. She is a former Director of Corporate Strategy and Head of Venture Strategy at AstraZeneca, where she was responsible for global corporate venturing activities, including the creation and $40M financing of the company’s first spinout, Albireo Pharma. She has also held posts in clinical research, licensing, M&A, venture capital and the NHS. This varied experience has given her an in-depth understanding of what is required to translate cutting edge science into commercial reality. Véronique is a non-executive director of International Biotechnology Trust plc. and of the Stevenage Bioscience Catalyst. She is a member of the Scientific Committee of Breast Cancer Now, and of the Council and Finance and Investment Committee of Queen Mary University London (QMUL). She sits on the advisory board of QMUL School of Business and Management and the QMUL Life Sciences in Whitechapel initiative.

Mr Paul O'Donohoe

Senior Director, eCOA Product and Science at Medidata Solutions

Paul O’Donohoe

Paul O’Donohoe is Senior Director, eCOA (electronic clinical outcome assessment) and Mobile Health at Medidata Solutions, a clinical software platform provider. He is responsible for developing the company's

 scientific expertise for electronic clinical outcome assessments and mobile health in clinical trials, and supports internal teams and Sponsors around the implementation of industry and regulatory best practices in studies using eCOA. He is passionate about developing the field of eCOA and mobile health through research and active involvement in industry consortia, and is currently the Industry Vice-Director of the C-Path ePRO Consortium.

Paul O’Donohoe can advise on:

  • Development of fit for purpose questionnaires for use in clinical research
  • Best practices for the implementation of patient questionnaires on electronic systems (e.g. smartphones, tablet computers, web-systems)
  • Use of wearable devices and sensors in clinical research
  • The regulatory landscape around the use of technology in clinical research
  • Career development for early career researchers

Dr Bobby Kaura

Seed Investment, EMEA Outreach & International Development, Illumina Accelerator

Bobby helped co-launch the Cambridge Accelerator, a genomics and VC backable company creation engine. Bobby Kaura Previously, he was responsible for heading commercial market and business development for Illumina EMEA with a focus on how genomics can enable precision health through the application of next-generation sequencing technologies.  He advocates for building ecosystems that support better population and patient outcomes with partners involved in driving forward UK life sciences. Before joining Illumina, he worked in the NHS to deliver sustainable transformation programs and spent several years working in the pharma industry across early research & development, strategic projects (executive) office and leading the UK value-based medicine and pricing innovation stream.

He is a member of the advisory board at Praesens Foundation (set-up to provide access to health programs, to communities in hard-to-reach regions and resource-limited settings), Mentor at Cambridge Judge Business School, NHS Innovation Accelerator and NIHR. In addition, he advises health, tech and blockchain startups.

Bobby read his B.Sc in Biology, with a focus on neuroscience and genomics, and an M.Sc in IT from the Queen Mary University of London.

Bobby Kaura can advise on:

  • Strategy and Execution
  • Market and Business Development
  • Leadership and Mentoring
  • Pharma and Diagnostics (personalised healthcare)
  • Precision health and (gen)omics and application of next generation sequencing

Please contact the Translational Research Office if you would like to book an appointment with an expert.

On this page